{
    "nct_id": "NCT00065767",
    "title": "Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2015-10-01",
    "description_brief": "The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.",
    "description_detailed": "The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication (classified as Selective Estrogen Receptor Modulators (SER's)) approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease. Patients who volunteer for this study will need to visit the clinic 7 times (participate) over a period of five months and will receive either raloxifene or a harmless, inactive pill called a placebo. Neither the volunteers nor the study staff will know which type of pill a patient receives. Patients must be generally healthy and have mild-to-moderate dementia. There must be a patient caregiver who can watch for side effects and ensure that the patient takes the study pills on schedule over a period of three months.\n\nPatients will undergo neuropsychological tests and an evaluation of the ability to live independently at each visit as well as laboratory evaluations, such as the taking of blood. Each visit will last approximately 3 hours. A total of 20 patients is being recruited to participate in this study at the University of Wisconsin.",
    "phase": [
        "PHASE2",
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Raloxifene \u2014 selective estrogen receptor modulator (SERM); oral, estrogen-like medication approved for osteoporosis"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The study tests raloxifene to \"improv[e] memory and the ability to live independently\" in postmenopausal women with Alzheimer's disease, indicating the intended effect is to improve cognition/function rather than directly target canonical AD pathology (amyloid or tau). Raloxifene is an estrogen-like SERM (not a biologic) so mechanistically it acts via estrogen receptors rather than as an anti-amyloid/tau agent. \ue200cite\ue202turn0search5\ue202turn0search2\ue201",
        "Act: Extracted details \u2014 drug: raloxifene (SERM), indication in trial: improve memory/independence in postmenopausal women with AD, comparator: placebo. Raloxifene is FDA\u2011approved for osteoporosis and has been evaluated in cognitive endpoints and AD pilot trials (e.g., a randomized pilot in women with AD showing no significant cognitive benefit; prior large MORE trial found reduced risk of MCI at a higher dose). These sources describe the drug class, approval, and cognitive/AD trial context. \ue200cite\ue202turn0search6\ue202turn0search1\ue202turn0search0\ue201",
        "Reflect: Classification justification \u2014 raloxifene is a small\u2011molecule, orally active SERM (not a biologic), and the trial's stated goal is to improve memory and daily functioning. This aligns with the 'Cognitive enhancer' category (category 3). Note ambiguity: some preclinical/epidemiologic data suggest neuroprotective effects and some prevention trials (MORE) examined dementia outcomes, so one could argue for a disease\u2011modifying intent in prevention contexts; however this specific trial title and description focus on improving cognition/independence in patients with AD, supporting the 'cognitive enhancer' classification. Key supporting literature: pilot AD RCT (no significant benefit), MORE prevention results (reduced MCI risk at 120 mg), and mechanistic/neuroprotection studies of raloxifene. \ue200cite\ue202turn0search5\ue202turn0search0\ue202turn0search2\ue201"
    ],
    "agent_type": "L) Growth Factors and Hormones",
    "explanation_agent": [
        "Reason: The intervention is raloxifene, a selective estrogen receptor modulator (SERM) that acts via estrogen receptors (hormone signaling) and the trial aim is to improve cognition/function in postmenopausal women with AD rather than to target canonical AD proteinopathies (amyloid or tau). \ue200cite\ue202turn0search6\ue202turn0search3\ue201",
        "Act: Extracted details \u2014 drug: raloxifene (oral SERM), approved for osteoporosis and evaluated for cognitive endpoints in postmenopausal women with and without AD; this trial\u2019s stated goal is cognitive enhancement/functional improvement in women with AD. Clinical data: a randomized pilot AD trial found no significant cognitive benefit at 12 months, while the larger MORE prevention trial reported a reduced risk of mild cognitive impairment at 120 mg/day. These facts support that the drug\u2019s primary biological target is the estrogen/hormone receptor pathway rather than amyloid or tau. \ue200cite\ue202turn0search3\ue202turn0search5\ue202turn0search6\ue201",
        "Reflect: Classification justification \u2014 raloxifene modulates estrogen receptor/hormone signaling, which maps directly to CADRO category L) Growth Factors and Hormones. While the trial is described functionally as a 'cognitive enhancer' and some neuroprotective hypotheses exist, the mechanistic target is a hormone receptor, not neurotransmitter receptors or amyloid/tau. Therefore L) Growth Factors and Hormones is the most specific and appropriate CADRO classification. \ue200cite\ue202turn0search6\ue202turn0search2\ue201",
        "Web search results (key sources used): 1) StatPearls summary of raloxifene mechanism (binds estrogen receptors; SERM). \ue200cite\ue202turn0search6\ue201 2) Raloxifene for women with Alzheimer disease \u2014 randomized controlled pilot trial (Neurology/PMC) showing no significant cognitive benefit in this AD pilot. \ue200cite\ue202turn0search3\ue202turn0search1\ue201 3) MORE trial (Multiple Outcomes of Raloxifene Evaluation) \u2014 randomized trial reporting reduced risk of mild cognitive impairment at 120 mg/day. \ue200cite\ue202turn0search5\ue202turn0search4\ue201 4) Systematic review of raloxifene and cognition summarizing mixed results and the MORE findings. \ue200cite\ue202turn0search2\ue201"
    ]
}